Raymond James & Associates
LRMR icon

Raymond James & Associates’s Larimar Therapeutics LRMR Stock Holding History

Raymond James & Associates’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,343
Closed -$898K – 2371
2015
Q3 		$898K Buy
+2,343
New +$1.06M ﹤0.01% 1651

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Raymond James & Associates's LRMR Position: Q4 2015 in Review

Raymond James & Associates sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 2,343 shares — an estimated $898K sold.

Raymond James & Associates first reported a position in LRMR in Q3 2015 and held it in 1 quarter. The position peaked at $898K in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Raymond James & Associates reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Raymond James & Associates sold 2,343 Larimar Therapeutics shares in Q4 2015, an estimated $898K.
  • Raymond James & Associates first reported a position in Larimar Therapeutics in Q3 2015 and held it in 1 quarter.
  • Raymond James & Associates's Larimar Therapeutics position peaked at $898K in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Raymond James & Associates's 13F filing for Q4 2015, filed 16 Feb 2016.